What did Brian Savage receive from his TEVA restricted share units?

Each restricted share unit provided a contingent right to one TEVA Ordinary Share or equivalent cash value. On March 3, 2026, 3,461 restricted share units vested and were converted into 3,461 Ordinary Shares as part of his equity compensation package.

How are TEVA Ordinary Shares and American Depositary Shares related in this filing?

The filing notes that TEVA Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one Ordinary Share, providing an equivalent economic interest for holders using the depositary share structure.

What was the vesting schedule for Brian Savage’s TEVA restricted share units?

Restricted share units were granted on March 3, 2023, with 3,461 units vesting on each of March 3, 2024, 2025, and 2026, and another 3,461 scheduled to vest on March 3, 2027, forming a four-year vesting pattern.

Teva (NYSE: TEVA) legal chief sells shares to cover RSU taxes

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD reported insider equity transactions by Interim Chief Legal Officer Brian Savage. On March 3, 2026, he exercised 3,461 Restricted Share Units, converting them into 3,461 Ordinary Shares at a stated price of $0.0000 per share.

Following this conversion, he held 4,200 Ordinary Shares, then sold 1,274 Ordinary Shares at a weighted average price of $32.3599 per share to cover tax withholding obligations, leaving 2,926 Ordinary Shares held directly.

Insider Trade Summary

Net Seller: 1,274 shares ($41,227)

Net Sell 3 txns

Insider Savage Brian

Role Interim Chief Legal Officer

Sold 1,274 shs ($41K)

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	3,461	$0.00	--
Exercise	Ordinary Shares	3,461	$0.00	--
Sale	Ordinary Shares	1,274	$32.3599	$41K

Holdings After Transaction: Restricted Share Units — 3,461 shares (Direct); Ordinary Shares — 4,200 shares (Direct)

Footnotes (1)

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 3, 2023, with 3,461 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 3,461 vesting on March 3, 2027.

Form 4 Insider Transactions: What Each Field Means →

03/05/2026 - 04:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savage Brian

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A STREET

(Street)

TEL AVIV

6944020

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Interim Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	03/03/2026		M		3,461	A	⁽²⁾	4,200	D
Ordinary Shares⁽¹⁾	03/03/2026		S		1,274⁽³⁾	D	$32.3599⁽⁴⁾	2,926	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽²⁾	03/03/2026		M			3,461	⁽⁵⁾	⁽⁵⁾	Ordinary Shares⁽¹⁾	3,461	$0	3,461	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

5. Restricted share units were granted on March 3, 2023, with 3,461 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 3,461 vesting on March 3, 2027.

	/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did TEVA Interim Chief Legal Officer Brian Savage report?

Brian Savage reported exercising 3,461 restricted share units into 3,461 Ordinary Shares and selling 1,274 Ordinary Shares. The transactions occurred on March 3, 2026, and were related to the vesting and tax withholding on his equity compensation awards.

How many TEVA shares did Brian Savage sell and at what price?

Brian Savage sold 1,274 Ordinary Shares of TEVA at a weighted average price of $32.3599 per share. The shares were sold in multiple trades between $31.72 and $32.865 to satisfy tax withholding obligations tied to vested restricted share units.

How many TEVA shares does Brian Savage hold after these transactions?

After converting restricted share units and selling shares for tax withholding, Brian Savage directly holds 2,926 Ordinary Shares of TEVA. This balance reflects his position following the March 3, 2026 open-market sales and equity award vesting activity.

Why were some of Brian Savage’s TEVA shares sold on March 3, 2026?

The 1,274 TEVA Ordinary Shares sold by Brian Savage represent shares required to be sold to cover tax withholding obligations. These obligations arose in connection with the vesting of restricted share units granted as part of his compensation.